Head to Head Survey: Kaya (OTCMKTS:KAYS) & Biomea Fusion (NASDAQ:BMEA)

Kaya (OTCMKTS:KAYS) and Biomea Fusion (NASDAQ:BMEA) are both small-cap consumer discretionary companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

Risk and Volatility

Kaya has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Biomea Fusion has a beta of -0.43, indicating that its stock price is 143% less volatile than the S&P 500.

Institutional and Insider Ownership

96.7% of Biomea Fusion shares are owned by institutional investors. 23.5% of Kaya shares are owned by insiders. Comparatively, 27.6% of Biomea Fusion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Kaya and Biomea Fusion”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kaya	$200,000.00	5.54	$1.61 million	$0.02	2.50
Biomea Fusion	N/A	N/A	-$117.25 million	($3.57)	-3.39

Kaya has higher revenue and earnings than Biomea Fusion. Biomea Fusion is trading at a lower price-to-earnings ratio than Kaya, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kaya and Biomea Fusion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kaya	260.23%	-9.79%	652.87%
Biomea Fusion	N/A	-91.86%	-76.56%

Analyst Ratings

This is a breakdown of current recommendations for Kaya and Biomea Fusion, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kaya	0	0	0	0	N/A
Biomea Fusion	0	2	8	2	3.00

Biomea Fusion has a consensus price target of $29.40, suggesting a potential upside of 142.37%. Given Biomea Fusion’s higher possible upside, analysts plainly believe Biomea Fusion is more favorable than Kaya.

Summary

Kaya beats Biomea Fusion on 8 of the 13 factors compared between the two stocks.

About Kaya

Kaya Holdings, Inc., a vertically integrated legal cannabis enterprise, engages in the operation of psychedelic treatment clinics and medical cannabis dispensaries primarily in the United States. It offers a range of cannabis products, including flower, oils, vape cartridges and cannabis infused confections, baked goods, and beverages. The company also operates retail outlets under the Kaya Shack brand name, as well as offers strain specific cannabis cigarettes under the Kaya Buddies name, and strains of cannabis under the Kaya Farms name. In addition, it is involved in the development of a psychedelic treatment center under The Sacred Mushroom name, that provides its guests access to psilocybin treatments, located in Portland, Oregon. The company was formerly known as Alternative Fuels America, Inc. and changed its name to Kaya Holdings, Inc. in April 2015. Kaya Holdings, Inc. is headquartered in Fort Lauderdale, Florida.

About Biomea Fusion

Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.